14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CNSY vs CRIS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Curis Inc (CRIS) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNSY carries a Unified Composite Score of 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin), whereas CRIS carries 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin).
Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. CRIS 38.7/100 SELL), CRIS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-833.4% vs. N/A operating margin) and revenue trajectory (-66.0% vs. N/A YoY).
Technical & Structure Timing Caution: CNSY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile CRIS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNSY vs CRIS. Trailing 12-month operating profitability (CNSY N/A vs CRIS -833.4%) and valuation multiples (CNSY N/M vs CRIS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.8M market capitalization and -833.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CNSY vs CRIS Key Questions & Quantitative Answers
As of Nov 16, 2026, Curis Inc (CRIS) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNSY carries a Unified Composite Score of 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin), whereas CRIS carries 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin). Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. CRIS 38.7/100 SELL), CRIS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-833.4% vs. N/A operating margin) and revenue trajectory (-66.0% vs. N/A YoY). Technical & Structure Timing Caution: CNSY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile CRIS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRIS leads the Growth & Scale pillar: CNSY posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CRIS at -66.0% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (N/A gross margin, -833.4% operating margin). On trailing 12-month operating scale, CNSY generates N/A in USD-normalized revenue versus $4.3M for CRIS. In operating R&D and SG&A reinvestment, CNSY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRIS.
CRIS screens cheaper on headline valuation multiples. CNSY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CRIS trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNSY (N/A ROE) versus CRIS (-693.9% ROE) capital efficiency.
In options market volatility and institutional positioning, CNSY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.54β · 228% Vol realized risk). By comparison, CRIS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.40β · 269% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.